Nadezhada L. Mironova

Dr. Nadezhada L. Mironova

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Journal of Controlled Release
Verified
Journal Article
Closed access
OMOleg V. Markov
Oleg V. Markov
NMNadezhada L. Mironova
Nadezhada L. Mironova
ESElena Shmendel
Elena Shmendel
RSRoman N. Serikov
Roman N. Serikov
NMNina G. Morozova
Nina G. Morozova
MZMarina Zenkova
Marina Zenkova

1 June 2012 in Journal of Controlled Release
Verified
Journal Article
Closed access
OMOleg V. Markov
Oleg V. Markov
NMNadezhada L. Mironova
Nadezhada L. Mironova
MMMikhail Maslov
Mikhail Maslov
IPIvan A. Petukhov
Ivan A. Petukhov
NMNina G. Morozova
Nina G. Morozova
MZMarina A. Zenkova
Marina A. Zenkova

Verified
Journal Article
Open access
PDF file
Khetam SounbuliKhetam Sounbuli
Khetam Sounbuli
NMNadezhada L. Mironova
Nadezhada L. Mironova
LALyudmila Aleksandrovna Alekseeva
Lyudmila Aleksandrovna Alekseeva
Neutrophils represent the most abundant cell type of leukocytes in the human blood and have been considered a vital player in the innate immune system and the first line of defense against invading pathogens. Recently, several studies showed that neutrophils play an active role in the immune response during cancer development. They exhibited both pro-oncogenic and anti-tumor activities under the influence of various mediators in the tumor microenvironment. Neutrophils can be divided into several subpopulations, thus contradicting the traditional concept of neutrophils as a homogeneous population with a specific function in the innate immunity and opening new horizons for cancer therapy. Despite the promising achievements in this field, a full understanding of tumor–neutrophil interplay is currently lacking. In this review, we try to summarize the current view on neutrophil heterogeneity in cancer, discuss the different communication pathways between tumors and neutrophils, and focus on the implementation of these new findings to develop promising neutrophil-based cancer therapies.

1 April 2017 in Biomaterials
Verified
Journal Article
Closed access
OPOlga A. Patutina
Olga A. Patutina
Elena V. BichenkovaElena V. Bichenkova
Elena V. Bichenkova
SMSvetlana Miroshnichenko
Svetlana Miroshnichenko
NMNadezhada L. Mironova
Nadezhada L. Mironova
LTLinda T. Trivoluzzi
Linda T. Trivoluzzi
MZMarina Zenkova
Marina Zenkova

1 April 2011 in Biochimie
Verified
Journal Article
Closed access
OPOlga Patutina
Olga Patutina
NMNadezhada L. Mironova
Nadezhada L. Mironova
ERElena Ryabchikova
Elena Ryabchikova
NPNelly Popova
Nelly Popova
VNValery Nikolin
Valery Nikolin
MZMarina Zenkova
Marina Zenkova

1 July 2013 in Cell Cycle
Verified
Journal Article
Open access
PDF file
NMNadezhada L. Mironova
Nadezhada L. Mironova
IPIrina Petrushanko
Irina Petrushanko
OPOlga Patutina
Olga Patutina
ASAexandra V. Sen’kova
Aexandra V. Sen’kova
OSOlga V. Simonenko
Olga V. Simonenko
AMAlexander Makarov
Alexander Makarov
Exogenous ribonucleases are known to inhibit tumor growth via apoptosis induction in tumor cells, allowing to consider them as promising anticancer drugs for clinical application. In this work the antitumor potential of binase was evaluated in vivo and the mechanism of cytotoxic effect of binase on tumor cells was comprehensively studied in vitro. We investigated tumoricidal activity of binase using three murine tumor models of Lewis lung carcinoma (LLC), lymphosarcoma RLS40 and melanoma B-16. We show for the first time that intraperitoneal injection of binase at a dose range 0.1–5 mg/kg results in retardation of primary tumor growth up to 45% in LLC and RLS40 and inhibits metastasis up to 50% in LLC and RLS40 and up to 70% in B-16 melanoma. Binase does not exhibit overall toxic effect and displays a general systemic and immunomodulatory effects. Treatment of RLS40-bearing animals with binase together with polychemotherapy revealed that binase decreases the hepatotoxicity of polychemotherapy while maintaining its antitumor effect. It was demonstrated that the cytotoxic effect of binase is realized via the induction of the intrinsic and extrinsic apoptotic pathways. Activation of intrinsic apoptotic pathway is manifested by a drop of mitochondrial potential, increase in calcium concentration and inhibition of respiratory activity. Subsequent synthesis of TNF-α in the cells under the action of binase triggers extrinsic apoptotic pathway through the binding of TNF with cell-death receptors and activation of caspase 8. Thus binase is a potential anticancer therapeutics inducing apoptosis in cancer cells.